Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 08, 2016 3:42 AM ET

Biotechnology

Company Overview of Advaxis, Inc.

Company Overview

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac (ADXS-HPV), an Lm-LLO immunotherapy product candidate, which completed its Phase II study used for the treatment of human papilloma virus (HPV) associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen (PSA) antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candida...

305 College Road East

Princeton, NJ 08540

United States

Founded in 2002

48 Employees

Phone:

609-452-9813

Fax:

609-452-9818

Key Executives for Advaxis, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice President
Age: 46
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice President
Age: 55
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.

Advaxis, Inc. Key Developments

Advaxis Appoints Bradley Monk as Lead Cervical Cancer Advisor

Advaxis, Inc. announced the appointment of Bradley J. Monk, MD, FACOG, FACS as Lead Cervical Cancer Advisor to the Company. Dr. Monk will be leading the development of Advaxis Lm Technology platform and assisting with the Company's multiple clinical programs, including those in HPV-associated cancers (cervical, anal, and head and neck), HER2 expressing tumors and prostate cancer. Dr. Monk brings to Advaxis more than 25 years of experience in medical oncology and clinical research. Notably, he serves as the co-primary investigator of GOG 0265. Dr. Monk is currently director of the Division of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.

Advaxis, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016

Advaxis, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016 . Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.

FDA Lifts Advaxis, Inc.'s Clinical Hold

Advaxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac (formerly ADXS-HPV), ADXS-PSA and ADXS-HER2. Advaxis will therefore resume all clinical trials with axalimogene filolisbac, ADXS-PSA and ADXS-HER2. In October of 2015, Advaxis received notification from the FDA that its IND applications for axalimogene filolisbac were put on clinical hold in response to the company’s submission of a safety report to the FDA. The clinical hold also included the INDs for ADXS-PSA and ADXS-HER2. Following discussions with the FDA and in accordance with their recommendations, the company agreed to implement certain risk mitigation measures, including revised study protocol inclusion /exclusion criteria, post-administration antibiotic treatment and patient surveillance and monitoring measures.

Similar Private Companies By Industry

Company Name Region
AxoTect, Inc. United States
MonoSol Rx Inc. United States
NeoClone Biotechnology International LLC United States
MediGene, Inc. United States
RIT Oncology, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Advaxis, Inc., please visit www.advaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.